Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with severe/very severe COVID-19 illness. The patient’s Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Condition or disease: severe/very severe COVID-19 illness.  Intervention/treatment: Drug Ruxolitinib (Jakavi)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff. For general information, Learn About Clinical Studies.

Criteria for inclusion and exclusion and further details about this trial

Full details for this trial can be found here…

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04337359